The alliance will combine this technology with Boehringer’s research and development expertise to develop a first-in-class treatment for patients with eye diseases, Surrozen announced.

Bayer said on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron (REGN.O), has been shown to work as well when given at a higher dose at a longer interval between injections.